Download PDF
Thromb Haemost 2004; 92(05): 940-946
DOI: 10.1160/TH04-02-0081
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH

Effects of heparin and low-molecular-weight heparins on bone mechanical properties in rats

Joanna Folwarczna
1   Department of Pharmacology, Medical University of Silesia, Sosnowiec, Poland
,
Waldemar Janiec
1   Department of Pharmacology, Medical University of Silesia, Sosnowiec, Poland
,
Leszek Śliwiński
1   Department of Pharmacology, Medical University of Silesia, Sosnowiec, Poland
› Author Affiliations
Further Information

Publication History

Received 09 February 2004

Accepted after resubmission 04 July 2004

Publication Date:
04 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

Long-term administration of heparin can be associated with development of osteoporosis. The present study was carried out to compare the effects of standard heparin and two low-molecular-weight heparins (nadroparin and enoxaparin) on bone mechanical properties in rats. The experiment was conducted on 3-month-old female Wistar rats. Standard heparin was administered in doses of 1000 or 2000 IU/kg sc daily, nadroparin and enoxaparin were administered in doses of 1000 or 2000 anti-Xa IU/kg sc daily, for 28 days. Bone mass, length, diameter, mineral content and mechanical properties of the whole femur (extrinsic stiffness, ultimate and breaking load, deformation caused by the applied load) and the femoral neck (load at fracture) were examined. Standard heparin (2000 IU/kg sc daily) weakened the femoral neck. Enoxaparin and the higher doses of standard heparin and nadroparin induced similar unfavourable changes in mechanical properties of the whole femur; the changes were noticeable the most after administration of enoxaparin.

Keywords

Heparin - nadroparin - enoxaparin - bones - rats
 

  • References

  • 1 Ginsberg JS, Kowalchuk G, Hirsh J. et al. Heparin effect on bone density. Thromb Haemost 1990; 64: 286-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Dahlman TC, Sjöberg HE, Ringertz H. Bone mineral density during long-term prophylaxis with heparin in pregnancy. Am J Obstet Gynecol 1994; 170: 1315-20.
    CrossrefPubMedGoogle Scholar
  • 3 Barbour LA, Kick SD, Steiner JF. et al. A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynecol 1994; 170: 862-9.
    CrossrefPubMedGoogle Scholar
  • 4 Douketis JD, Ginsberg JS, Burrows RF. et al. The effects of long-term heparin therapy during pregnancy on bone density. A prospective matched cohort study. Thromb Haemost 1996; 75: 254-7.
    PubMedGoogle Scholar
  • 5 Mätzsch T, Bergqvist D, Hedner U. et al. Effects of low molecular weight heparin and unfragmented heparin on induction of osteoporosis in rats. Thromb Haemost 1990; 63: 505-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Muir JM, Andrew M, Hirsh J. et al. Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo. Blood 1996; 88: 1314-20.
    PubMedGoogle Scholar
  • 7 Muir JM, Hirsh J, Weitz JI. et al. A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats. Blood 1997; 89: 3236-42.
    PubMedGoogle Scholar
  • 8 Murray WJ, Lindo VS, Kakkar VV. et al. Long-term administration of heparin and heparin fractions and osteoporosis in experimental animals. Blood Coagul Fibrinolysis 1995; 06: 113-8.
    CrossrefPubMedGoogle Scholar
  • 9 Mutoh S, Takeshita N, Yoshino T. et al. Characterization of heparin-induced osteopenia in rats. Endocrinology 1993; 133: 2743-8.
    CrossrefPubMedGoogle Scholar
  • 10 Monreal M, Viñas L, Monreal L. et al. Heparin-related osteoporosis in rats. A comparative study between unfractioned heparin and a low-molecular-weight heparin. Haemostasis 1990; 20: 204-7.
    PubMedGoogle Scholar
  • 11 Martineau P, Tawil N. Low-molecular-weight heparins in the treatment of deep-vein thrombosis. Ann Pharmacother 1998; 32: 588-98 601..
    CrossrefPubMedGoogle Scholar
  • 12 Hirsh J, Warkentin TE, Shaughnessy SG. et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119 (01) 64S-94S.
    CrossrefPubMedGoogle Scholar
  • 13 Laurent P, Dussarat GV, Bonal J. et al. Low molecular weight heparins: a guide to their optimum use in pregnancy. Drugs 2002; 62: 463-77.
    CrossrefPubMedGoogle Scholar
  • 14 Backos M, Rai R, Thomas E. et al. Bone density changes in pregnant women treated with heparin: a prospective, longitudinal study. Hum Reprod 1999; 14: 2876-80.
    CrossrefPubMedGoogle Scholar
  • 15 Shefras J, Farquharson RG. Bone density studies in pregnant women receiving heparin. Eur J Obstet Gynecol Reprod Biol 1996; 65: 171-4.
    CrossrefPubMedGoogle Scholar
  • 16 Casele HL, Laifer SA. Prospective evaluation of bone density in pregnant women receiving the low molecular weight heparin enoxaparin sodium. J Matern Fetal Med 2000; 09: 122-5.
    PubMedGoogle Scholar
  • 17 Monreal M, Lafoz E, Olive A. et al. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 1994; 71: 7-11.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Nelson-Piercy C, Letsky EA, de Swiet M. Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk. Am J Obstet Gynecol 1997; 176: 1062-8.
    CrossrefPubMedGoogle Scholar
  • 19 Pettila V, Leinonen P, Markkola A. et al. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractioned heparin or LMW heparin. Thromb Haemost 2002; 87: 182-6.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Wawrzyńska L, Tomkowski WZ, Przedlacki J. et al. Changes in bone density during longterm administration of low-molecular-weight heparins or acenocoumarol for secondary prophylaxis of venous thromboembolism. Pathophysiol Haemost Thromb 2003; 33: 64-7.
    PubMedGoogle Scholar
  • 21 Shaughnessy SG, Young E, Deschamps P. et al. The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. Blood 1995; 86: 1368-73.
    PubMedGoogle Scholar
  • 22 Bhandari M, Hirsh J, Weitz JI. et al. The effects of standard and low molecular weight heparin on bone nodule formation in vitro. Thromb Haemost 1998; 80: 413-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Nishiyama M, Itoh F, Ujiie A. Low-molecularweight heparin (dalteparin) demonstrated a weaker effect on rat bone metabolism compared with heparin. Jpn J Pharmacol 1997; 74: 59-68.
    CrossrefPubMedGoogle Scholar
  • 24 Folwarczna J, Janiec W, Barej M, Cegie-la U, Pytlik M, Kaczmarczyk-Sedlak I. Effects of nadroparin on bone histomorphometric parameters in rats. Pol J Pharmacol 2004; 56: 337-43.
    PubMedGoogle Scholar
  • 25 Eikelboom JW, Hankey GJ. Low molecular weight heparins and heparinoids. Med J Aust 2002; 177: 379-83.
    PubMedGoogle Scholar
  • 26 Pytlik M, Folwarczna J, Janiec W. Effect of doxycycline on mechanical properties of bones in rats with ovariectomy-induced osteopenia. Calcif Tissue Int 2004; 75: 225-30.
    CrossrefPubMedGoogle Scholar
  • 27 Mätzsch T, Bergqvist D, Hedner U. et al. Heparin-induced osteoporosis in rats. Thromb Haemost 1986; 56: 293-4.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Walenga JM, Bick RL. Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other side effects of heparin therapy. Med Clin North Am 1998; 82: 635-58.
    CrossrefPubMedGoogle Scholar
  • 29 Akkas N, Yeni YN, Turan B. et al. Effect of medication on biomechanical properties of rabbit bones: heparin induced osteoporosis. Clin Rheumatol 1997; 16: 585-95.
    CrossrefPubMedGoogle Scholar
  • 30 Turner CH, Burr DB. Basic biomechanical measurements of bone: a tutorial. Bone 1993; 14: 595-608.
    CrossrefPubMedGoogle Scholar
  • 31 Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000; 21: 115-37.
    PubMedGoogle Scholar
  • 32 Folwarczna J, Janiec W, Gawor M. et al. Effects of enoxaparin on histomorphometric parameters of bones in rats. Pol J Pharmacol. 2004 56. accepted for publication.
    PubMedGoogle Scholar
  • 33 Kock HJ, Handschin AE. Osteoblast growth inhibition by unfractionated heparin and by low molecular weight heparins: an in-vitro investigation. Clin Appl Thromb Hemost 2002; 08: 251-5.
    CrossrefPubMedGoogle Scholar
  • 34 Matziolis G, Perka C, Disch A. et al. Effects of fondaparinux compared with dalteparin, enoxaparin and unfractionated heparin on human osteoblasts. Calcif Tissue Int 2003; 73: 370-9.
    CrossrefPubMedGoogle Scholar